Since mAbs against CGRP have demonstrated breakthrough efficacy for the prevention of episodic and chronic migraine, a peptide immunogen designed to stimulate the production of endogenous antibodies against CGRP might provide an attractive option for the prevention of migraine. This evidence concerns the gene CALCA and migraine disorder.